<DOC>
	<DOC>NCT01435655</DOC>
	<brief_summary>Tafamidis has been developed as an oral specific stabilizer of transthyretin tetramer.</brief_summary>
	<brief_title>The Effect Of Tafamidis For The Transthyretin Amyloid Polyneuropathy Patients With V30M Or Non-V30M Transthyretin</brief_title>
	<detailed_description />
	<mesh_term>Amyloidosis</mesh_term>
	<mesh_term>Polyneuropathies</mesh_term>
	<mesh_term>Amyloid Neuropathies</mesh_term>
	<mesh_term>Amyloid Neuropathies, Familial</mesh_term>
	<criteria>Transthyretin amyloid polyneuropathy with V30M or nonV30M transthyretin mutation. Subject had amyloid documented by biopsy in accordance with institutional site standard of care. Primary amyloidosis and secondary amyloidosis. History of liver transplant.</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>August 2015</verification_date>
</DOC>